NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agilysys, Inc. (AGYS, Financial), Editas Medicine, Inc. (EDIT, Financial), The ExOne Company (XONE, Financial), Central Garden & Pet Company (CENTA, Financial), Quality Systems, Inc. (QSII, Financial), and Stemline Therapeutics, Inc. (STML, Financial), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
AGYS DOWNLOAD: http://Fundamental-Markets.com/register/?so=AGYS
EDIT DOWNLOAD: http://Fundamental-Markets.com/register/?so=EDIT
XONE DOWNLOAD: http://Fundamental-Markets.com/register/?so=XONE
CENTA DOWNLOAD: http://Fundamental-Markets.com/register/?so=CENTA
QSII DOWNLOAD: http://Fundamental-Markets.com/register/?so=QSII
STML DOWNLOAD: http://Fundamental-Markets.com/register/?so=STML
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Agilysys, Inc. (AGYS, Financial), Editas Medicine, Inc. (EDIT, Financial), The ExOne Company (XONE, Financial), Central Garden & Pet Company (CENTA, Financial), Quality Systems, Inc. (QSII, Financial), and Stemline Therapeutics, Inc. (STML, Financial) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 27th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
AGILYSYS, INC. (AGYS, Financial) REPORT OVERVIEW
Agilysys' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Agilysys reported revenue of $31.31MM vs $33.45MM (down 6.39%) and basic earnings per share -$0.08 vs -$0.08. For the twelve months ended March 31st, 2017 vs March 31st, 2016, Agilysys reported revenue of $127.68MM vs $120.37MM (up 6.07%) and basic earnings per share -$0.52 vs -$0.17. Agilysys is expected to report earnings on June 7th, 2018. The report will be for the fiscal period ending March 31st, 2018.
To read the full Agilysys, Inc. (AGYS, Financial) report, download it here: http://Fundamental-Markets.com/register/?so=AGYS
-----------------------------------------
EDITAS MEDICINE, INC. (EDIT, Financial) REPORT OVERVIEW
Editas Medicine's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Editas Medicine reported revenue of $3.67MM vs $0.90MM (up 308.35%) and basic earnings per share -$0.84 vs -$1.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Editas Medicine reported revenue of $13.73MM vs $6.05MM (up 126.80%) and basic earnings per share -$2.98 vs -$3.02. Editas Medicine is expected to report earnings on May 21st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.85. The estimated EPS forecast for the next fiscal year is -$3.32 and is expected to report on March 5th, 2019.
To read the full Editas Medicine, Inc. (EDIT, Financial) report, download it here: http://Fundamental-Markets.com/register/?so=EDIT
-----------------------------------------
THE EXONE COMPANY (XONE, Financial) REPORT OVERVIEW
The ExOne's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, The ExOne reported revenue of $20.19MM vs $14.63MM (up 37.99%) and basic earnings per share -$0.13 vs -$0.16. For the twelve months ended December 31st, 2017 vs December 31st, 2016, The ExOne reported revenue of $57.74MM vs $47.79MM (up 20.83%) and basic earnings per share -$1.25 vs -$0.92. The ExOne is expected to report earnings on May 10th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is -$0.31 and is expected to report on March 21st, 2019.
To read the full The ExOne Company (XONE, Financial) report, download it here: http://Fundamental-Markets.com/register/?so=XONE
-----------------------------------------
CENTRAL GARDEN & PET COMPANY (CENTA, Financial) REPORT OVERVIEW
Central Garden & Pet's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Central Garden & Pet reported revenue of $442.01MM vs $419.50MM (up 5.37%) and basic earnings per share $0.52 vs $0.15 (up 246.67%). For the twelve months ended September 30th, 2017 vs September 30th, 2016, Central Garden & Pet reported revenue of $2,054.48MM vs $1,829.02MM (up 12.33%) and basic earnings per share $1.57 vs $0.91 (up 72.53%). Central Garden & Pet is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.67.
To read the full Central Garden & Pet Company (CENTA, Financial) report, download it here: http://Fundamental-Markets.com/register/?so=CENTA
-----------------------------------------
QUALITY SYSTEMS, INC. (QSII, Financial) REPORT OVERVIEW
Quality's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Quality reported revenue of $131.72MM vs $127.87MM (up 3.01%) and basic earnings per share $0.02 vs $0.17 (down 88.24%). For the twelve months ended March 31st, 2017 vs March 31st, 2016, Quality reported revenue of $509.62MM vs $492.48MM (up 3.48%) and basic earnings per share $0.30 vs $0.09 (up 233.33%). Quality is expected to report earnings on May 18th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.18.
To read the full Quality Systems, Inc. (QSII, Financial) report, download it here: http://Fundamental-Markets.com/register/?so=QSII
-----------------------------------------
STEMLINE THERAPEUTICS, INC. (STML, Financial) REPORT OVERVIEW
Stemline Therapeutics' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Stemline Therapeutics reported revenue of $0.00MM vs $0.30MM and basic earnings per share -$0.93 vs -$0.56. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Stemline Therapeutics reported revenue of $0.90MM vs $1.04MM (down 13.75%) and basic earnings per share -$2.94 vs -$2.15. Stemline Therapeutics is expected to report earnings on May 9th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.67. The estimated EPS forecast for the next fiscal year is -$0.19 and is expected to report on March 15th, 2019.
To read the full Stemline Therapeutics, Inc. (STML, Financial) report, download it here: http://Fundamental-Markets.com/register/?so=STML
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
